|
Video: What is a Stock Split?
|
|
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Co.'s product candidates include GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers; and granulocyte macrophage colony-stimulating factor immunoadjuvant, which is to improve monocyte and neutrophil cytotoxicity against melanoma tumor cells and to improve activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies. According to our Greenwich LifeSciences stock split history records, Greenwich LifeSciences has had 0 splits. | |
|
Greenwich LifeSciences (GLSI) has 0 splits in our Greenwich LifeSciences stock split history database.
Looking at the Greenwich LifeSciences stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Greenwich LifeSciences shares, starting with a $10,000 purchase of GLSI, presented on a split-history-adjusted basis factoring in the complete Greenwich LifeSciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/28/2020 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$4.91 |
|
End price/share: |
$12.62 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
157.03% |
|
Average Annual Total Return: |
30.24% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$25,700.18 |
|
Years: |
3.57 |
|
|
|
|
|